Jaime Pons

Dr. Jaime Pons

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
VDVanessa Daza-Cajigal
Vanessa Daza-Cajigal
MSMarina Segura-Guerrero
Marina Segura-Guerrero
MLMaría López-Cueto
María López-Cueto
ÁRÁngel Robles-Marhuenda
Ángel Robles-Marhuenda
CCCarmen Camara
Carmen Camara
JPJaime Pons
Jaime Pons
Purpose: The clinical spectrum of common variable immunodeficiency (CVID) includes predisposition to infections, autoimmune/inflammatory complications and malignancy. Liver disease is developed by a proportion of patients with CVID, but limited evidence is available about its prevalence, pathogenesis and prognostic outcome. This lack of evidence leads to the absence of guidelines in clinical practice. In this study, we aimed at defining the characteristics, course and management of this CVID complication in Spain.Methods: Spanish reference centers were invited to complete a cross-sectional survey. Thirty-eight patients with CVID-related liver disease from different hospitals were evaluated by a retrospective clinical course review.Results: In this cohort, abnormal liver function and thrombocytopenia were found in most of the patients (95% and 79% respectively), in keeping with the higher incidence of abnormal liver imaging and splenomegaly. The most common histological findings included nodular regenerative hyperplasia (NRH) and lymphocytic infiltration, which have been associated with portal hypertension (PHTN) leading to a poorer prognosis. Autoimmune/inflammatory complications occurred in 82% of the CVID patients that developed liver disease and 52% of the patients treated with immunomodulators showed a reduction in the liver function tests’ abnormalities during treatment. Among the experts that conducted the survey, there was 80% or more consensus that the workup of CVID-related liver disease requires liver profile, abdominal ultrasound and transient elastography. The majority agreed that liver biopsy should be essential for diagnosis. There was 94% consensus that endoscopic studies should be performed in the presence of PHTN. However, there was 89% consensus that there is insufficient evidence on the management of these patients.Conclusion: Liver disease varies in severity and may contribute substantially to morbidity and mortality in patients with CVID. Hence the importance of close follow-up and screening of this CVID complication to prompt early targeted intervention. Further research is needed to evaluate the pathophysiology of liver disease in patients with CVID to identify personalized treatment options. This study emphasizes the urgent need to develop international guidelines for the diagnosis and management of this CVID complication.

1 December 2015 in Clinical Immunology
Verified
Journal Article
Closed access
ACAntonio Clemente
Antonio Clemente
JPJaime Pons
Jaime Pons
NLNallibe Lanio
Nallibe Lanio
VCVanesa Cunill
Vanesa Cunill
GFGuillem Frontera
Guillem Frontera
JFJoana M. Ferrer
Joana M. Ferrer

16 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
NMNatalia Martínez-Pomar
Natalia Martínez-Pomar
VCVanesa Cunill
Vanesa Cunill
MSMarina Segura-Guerrero
Marina Segura-Guerrero
EPElisabet Pol-Pol
Elisabet Pol-Pol
DODanilo Escobar Oblitas
Danilo Escobar Oblitas
JBJoana Maria Ferrer Balaguer
Joana Maria Ferrer Balaguer
The hyperinflammatory response caused by SARS-CoV-2 infection contributes to its severity, and many critically ill patients show features of cytokine storm (CS) syndrome. We investigated, by next-generation sequencing, 24 causative genes of primary immunodeficiencies whose defect predisposes to CS. We studied two cohorts with extreme phenotypes of SARS-CoV-2 infection: critical/severe hyperinflammatory patients (H-P) and asymptomatic patients (AM-risk-P) with a high risk (older age) to severe COVID-19. To explore inborn errors of the immunity, we investigated the presence of pathogenic or rare variants, and to identify COVID-19 severity-associated markers, we compared the allele frequencies of common genetic polymorphisms between our two cohorts. We found: 1 H-P carries the likely pathogenic variant c.887-2 A>C in the IRF7 gene and 5 H-P carries variants in the MEFV gene, whose role in the pathogenicity of the familial Mediterranean fever (FMF) disease is controversial. The common polymorphism analysis showed three potential risk biomarkers for developing the hyperinflammatory response: the homozygous haplotype rs1231123A/A-rs1231122A/A in MEFV gene, the IFNAR2 p.Phe8Ser variant, and the CARMIL2 p.Val181Met variant. The combined analysis showed an increased risk of developing severe COVID-19 in patients that had at least one of our genetic risk markers (odds ratio (OR) = 6.2 (95% CI) (2.430–16.20)).

6 August 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AFAndrea Ferranti-Ramos
Andrea Ferranti-Ramos
MAMarta Aguilar-Criado
Marta Aguilar-Criado
CACarmen L. Avendaño-Monje
Carmen L. Avendaño-Monje
MLMaría de Las Mercedes Díaz Luna
María de Las Mercedes Díaz Luna
CFCinthya M. Fusi-Velarde
Cinthya M. Fusi-Velarde
JPJaime Pons
Jaime Pons
Introduction: Human immunoglobulin (IG) therapy, administered intravenously (IVIG) or subcutaneously (SCIG), is a cornerstone treatment for primary and secondary immunodeficiencies (PID and SID) and is increasingly used in autoimmune and inflammatory diseases. Although generally safe, adverse drug reactions (ADR) may affect treatment adherence, patient safety, and quality of care. Practical recommendations for the prevention and management of IG-associated ADR remain limited. Objective: To develop expert-based recommendations for the prevention, monitoring, classification, and management of ADR associated with IVIG and SCIG therapy in patients with PID and SID. Methods: A modified Delphi consensus was conducted by the Immunodeficiency Group of the Spanish Society of Immunology (GISEI). An expert coordinating committee developed 44 preliminary statements based on scientific evidence and clinical experience. Statements covered eight domains, including administration practices, ADR classification, premedication, acute management, complementary studies, anti-IgA antibodies, and SCIG-related issues. A national panel of specialists evaluated each statement using a 6-point Likert scale. Consensus was defined as ≥75% agreement. Results: Forty-two recommendations achieved consensus and were included in the final document. High agreement was reached regarding individualized risk assessment, infusion rate adjustment, patient monitoring, and early ADR management. Most IVIG-related ADR were considered mild, occurring during or shortly after infusion, and generally not requiring treatment discontinuation. Premedication was recommended only for selected high-risk patients. SCIG was recognized as a safe and effective alternative associated with fewer systemic reactions and predominantly mild local ADR. The panel also highlighted the limited utility of serial anti-IgA antibody testing and emphasized patient education and periodic retraining for home-based SCIG administration. Discussion: This Delphi-based consensus provides practical and clinically applicable recommendations for the prevention and management of ADR associated with IVIG and SCIG therapy. These recommendations may contribute to standardizing clinical practice, improving patient safety, optimizing treatment tolerability, and reducing variability in IG administration across healthcare settings. Further prospective studies are needed to better define risk factors and preventive strategies for severe ADR associated with IG therapy.